2 unknown, 1 active not recruiting, 1 completed, 1 recruiting. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 2, Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow ANCA Associated Vasculitis: new trials by email Literature Review of ANCA Associated Vasculitis trials Research Report on ANCA Associated Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 8 | 2024-11-29 | 2025-04-11 |
| PR3-AAV Resilient Remission or PRRR Obinutuzumab, Rituximab - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Terminated | Mayo Clinic | 6 | 2023-06-30 | 2026-05-06 |
| ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) Sparsentan - ANCA Associated Vasculitis, Cardiovascular Diseases | Phase 2 | Active not recruiting | University of Edinburgh | 32 | 2022-12-08 | 2026-08-26 |
| Rituximab and Belimumab Combination Therapy in PR3 Vasculitis Belimumab, Rituximab, Prednisolone - ANCA Associated Vasculitis, Granulomatosis With Polyangiitis | Phase 2 | Unknown | Rachel Jones | 31 | 2019-02-01 | 2022-03-08 |
| CMV Modulation of the Immune System in ANCA-associated Vasculitis Valaciclovir - ANCA Associated Vasculitis, CMV Infection | Phase 2 | Unknown | Professor Lorraine Harper | 38 | 2013-07-01 | 2016-11-30 |
| Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Rituximab - Systemic Lupus Erythematosus, ANCA Associated Vasculitis | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 20 | 2002-03-01 | 2006-02-17 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (6) · Granulomatosis with Polyangiitis (2) · Lupus Erythematosus, Systemic (2) · Cardiovascular Diseases (1) · Cytomegalovirus Infections (1) · Dermatomyositis (1) · Kidney Diseases (1) · Microscopic Polyangiitis (1) · Polymyositis (1) · Scleroderma, Diffuse (1) · Vasculitis (1)
Autoimmune Diseases (6) · Immune System Diseases (6) · Skin Diseases (6) · Skin Diseases, Vascular (6) · Skin and Connective Tissue Diseases (6) · Systemic Vasculitis (6) · Vascular Diseases (6) · Cardiovascular Diseases (5) · Vasculitis (5) · Connective Tissue Diseases (2) · Lung Diseases (2) · Lung Diseases, Interstitial (2) · Nervous System Diseases (2) · Respiratory Tract Diseases (2) · Brain Diseases (1)
Rituximab (3) · Immunotherapy, Adoptive (1) · Prednisolone (1) · Prednisone (1) · Valacyclovir (1) · belimumab (1) · obinutuzumab (1) · sparsentan (1)
Cambridge University Hospitals NHS Foundation Trust (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Mayo Clinic (1) · Professor Lorraine Harper (1) · Rachel Jones (1) · University of Edinburgh (1)
United Kingdom (4) · Italy (1) · United States (1)
David Jayne (1) · Ken Smith (1) · Lorraine Harper, MRCP PhD (1) · Maria Antonietta D'Agostino (1) · Neeraj Dhaun (1) · Rachel B Jones (1) · Ulrich Specks, MD (1)
PMID 26312852, PMID 27450392, PMID 30102389, PMID 33164993, PMID 36906660